These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 10157923)
1. Promotion of OTC products within a network-model HMO. Gilderman A; Shinmoto M; Andrews S Med Interface; 1996 Jun; 9(6):104-8. PubMed ID: 10157923 [TBL] [Abstract][Full Text] [Related]
3. Over-the-counter drugs as a new managed care benefit. Scheur BS; Aaron RM Med Interface; 1997 Feb; 10(2):88-94. PubMed ID: 10164797 [TBL] [Abstract][Full Text] [Related]
4. Should health plans offer an OTC drug benefit? Navarro RP Med Interface; 1996 Jun; 9(6):100-1, 108. PubMed ID: 10157922 [No Abstract] [Full Text] [Related]
5. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; final monograph for combination drug products. Final rule. Food and Drug Administration, HHS Fed Regist; 2002 Dec; 67(246):78158-72. PubMed ID: 12508820 [TBL] [Abstract][Full Text] [Related]
6. Over-the-counter (OTC) cough remedies. Med Lett Drugs Ther; 2001 Mar; 43(1100):23-5. PubMed ID: 11257716 [No Abstract] [Full Text] [Related]
7. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; amendment of monograph for OTC nasal decongestant drug products. Final rule. Fed Regist; 2006 Aug; 71(147):83358[sic., should be 43358]-63. PubMed ID: 16892519 [TBL] [Abstract][Full Text] [Related]
8. Allergy, cold sufferers must cope with effects of OTC medications. Vaughan E Occup Health Saf; 1991 Apr; 60(4):28, 30. PubMed ID: 1711185 [No Abstract] [Full Text] [Related]
9. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; amendment of final monograph for over-the-counter nasal decongestant drug products. Final rule. Food and Drug Administration, HHS Fed Regist; 2005 Oct; 70(195):58974-7. PubMed ID: 16217879 [TBL] [Abstract][Full Text] [Related]
12. The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: a microeconomic analysis. Shih YC; Prasad M; Luce BR Clin Ther; 2002 Apr; 24(4):701-16. PubMed ID: 12017413 [TBL] [Abstract][Full Text] [Related]
13. FDA launches campaign on OTC pain relief products. FDA Consum; 2004; 38(2):8. PubMed ID: 15101357 [TBL] [Abstract][Full Text] [Related]
14. Point/counterpoint. The HMO pharmacy benefit. In-house pharmacy administration: the benefits of integration. Penna P HMO; 1995; 36(4):56, 58-9. PubMed ID: 10166487 [No Abstract] [Full Text] [Related]
15. For young children, many OTC products are out in the cold. Sinclair E; Fiechtner HB S D Med; 2009 Jun; 62(6):236-7. PubMed ID: 19650276 [No Abstract] [Full Text] [Related]
16. Point/counterpoint. The HMO pharmacy benefit. Contracted pharmacy services: the value of a carve-out PBM. Reissman D HMO; 1995; 36(4):57, 60-1. PubMed ID: 10166488 [No Abstract] [Full Text] [Related]
17. Medicaid pharmacy program becoming model for improved care, reduced costs. Public Sect Contract Rep; 1997 Jun; 3(6):86-9. PubMed ID: 10175082 [No Abstract] [Full Text] [Related]
18. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy. Sullivan PW; Nair KV; Patel BV Am J Manag Care; 2005 Jun; 11(6):374-82. PubMed ID: 15974556 [TBL] [Abstract][Full Text] [Related]
19. OTC article makes headlines. Wasserman GS; Montgomery EJ Mo Med; 2009; 106(1):32. PubMed ID: 19248243 [No Abstract] [Full Text] [Related]